TrialCompass™ TCL
Back to trials
RecruitingPriority 4 · Lower priorityNCT04014374

Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab

ClinicalTrials.gov

Plain-language summary

This trial is testing allogeneic stem cell transplant (from a donor) for patients with adult T-cell leukemia/lymphoma (ATLL) or cutaneous T-cell lymphoma (CTCL) at various stages of their disease. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

Who can join (key eligibility)

  • Age 18 Years or older
  • See full trial listing for complete eligibility

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details

Learn more

What is CTCL?

Plain-language overview of CTCL plus all curated trials for this subtype.

Use our AI Assistant

Ask questions about this trial, eligibility, or T-cell lymphoma in general.

Generate a letter for your doctor

Create a printable letter to discuss this trial with your oncologist.

TrialCompass — Clinical Trial Summary

Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab

NCT04014374

Status: Recruiting | Priority: Lower

Plain-language summary

This trial is testing allogeneic stem cell transplant (from a donor) for patients with adult T-cell leukemia/lymphoma (ATLL) or cutaneous T-cell lymphoma (CTCL) at various stages of their disease. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

Who can join

  • Age 18 Years or older
  • See full trial listing for complete eligibility

What's being tested

Drugs / treatments:

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, blind

Enrollment target: 150 patients

Primary endpoint: Assess toxicities or complications of transplant among patients who were treated with mogamulizumab, alone or in combination

Ages: 18 Years to —

Start date: 2019-09-10 | Est. completion: 2030-02

Locations

1 US sites · 1 total

Wisconsin

Contact

Linda J Burns, MD | lburns@mcw.edu | 414-805-0714

Sponsor: Kyowa Kirin, Inc. (INDUSTRY)

Tags

ATLL · CTCL · any

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT04014374

Prepared using TrialCompass (trialcompass.com) on August 3, 2026. For informational purposes only. Always discuss with your healthcare team.